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intervention. Tbx2 is a transcription factor that was first identified in a senescence screen and acts at the transcriptional level by negatively regulating p21 in human, and p19 ARF in mouse.
Previously, Tbx2 has been found to be over-expressed in BRCA1 and BRCA2 associated tumors as well as melanoma and pancreatic cancer cell lines. In developmental studies, Tbx2 has been shown to form positive regulatory loops with SHH and BMP2 signaling. Interestingly, in a recent report, it was found that Tbx2 expression is increased 10-fold at the mRNA level in a highly osteoblastic metastatic bone lesion of a prostate cancer patient when compared to the highly osteolytic PC3 prostate cancer cells.
We found (in the preliminary data submitted in the original DOD grant application) that Tbx2, an anti-senescence transcription factor is over-expressed in a subset of human and mouse prostate cancer cell lines. Further we showed (in the original grant) that Tbx2 expression is regulated by androgens both in LNCaP cells and in the mouse prostate in vivo. Based on this preliminary data, Aim 1 proposes to study the androgen regulation of Tbx2. In Aim 2, we have proposed to study the in vivo effects of Tbx2 manipulation in prostate cancer cells using a tissue recombination approach to simulate the prostate microenvironment and also to study these Tbx2 manipulated prostate cancer cells in a bone microenvironment using the technique of bone intra-tibial inoculation. Aim 3 proposes to study the role of Tbx2 in the resistance to pharmacological agents like doxorubicin in prostate cancer cells. Overall, the grant proposes to study the role of Tbx2 in prostate cancer progression.
Body:
Task 1: Characterize androgen regulation of Tbx2.
Progress on Task 1 has been described in the report of 2008. PC3 cells when injected in the tibia are known to be osteolytic in nature. As analyzed by x-ray analysis after 3 weeks of inoculation, we found that PC3-Tbx2 DN cells were reduced in their ability to elicit an osteolytic response in the bone as compared to PC3-EV cells (Fig. 2) . Also, the size of PC3-Tbx2 DN lesions was smaller as compared to PC3-EV cell lesions as seen on X-ray as well as by H&E analyses (Fig. 3 ) of bone tibial sections performed after fixation of harvested tibiae. We are now increasing the number of mice in each group and quantitating the size of lesions by micro CT analysis.
In order to study Tbx2 role in bone metastases, we were also interested in developing a mouse model where the metastasis originates from the mouse prostate rather then a direct graft of cells within the tiba. Hepsin is a cell surface protease that is over-expressed in more than 90% of human prostate cancer cases. Our lab has previously developed the PB-hepsin/LPB- Tag We have not addressed this task partly or fully as yet. 
